Cosentyx has not been discontinued as of September 2021, according to the sources provided [1][2][3]. Cosentyx (secukinumab) is a biologic medication that is used to treat certain autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking a protein called interleukin-17A (IL-17A), which is involved in inflammation.

The drug was approved by the US Food and Drug Administration (FDA) in January 2015 [2]. Since then, it has been widely used as a treatment option for various autoimmune diseases. In fact, Cosentyx has been shown to be highly effective in clinical trials, with many patients experiencing significant improvement in their symptoms [3].

It is important to note that while Cosentyx has not been discontinued, it may not be suitable for everyone. Like all medications, it can cause side effects, and some people may not respond well to the drug. It is also a relatively expensive medication, which may limit its accessibility for some patients [3].

In conclusion, based on the sources provided, Cosentyx has not been discontinued as of September 2021. It remains an important treatment option for certain autoimmune conditions, although it may not be suitable for everyone. Patients should consult with their healthcare provider to determine if Cosentyx is an appropriate treatment option for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013855/